Dyax (DYAX) Said Study Shows DX-88 Provides Rapid and Sustained Relief for Hereditary Angioedema
Tweet Send to a Friend
Dyax Corp. (Nasdaq: DYAX) announced presentation of an integrated analysis of the two DX-88 Phase 3 studies demonstrating that treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
